19
Participants
Start Date
May 12, 2012
Primary Completion Date
June 7, 2013
Study Completion Date
June 7, 2013
Aes-103
300 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
Aes-103
1000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
Aes-103
2000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
Aes-103
4000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
Placebo
Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
US National Institutes of Health - National Heart, Lung, and Blood Institute, Bethesda
Collaborators (3)
SAIC-Frederick, Inc.
INDUSTRY
Therapeutics for Rare and Neglected Diseases (TRND)
NIH
QS Pharma
UNKNOWN
National Chung Cheng University
OTHER
Infrared Imaging and Thermometry Unit, Biomedical Engineering and Physical Science Shared Resource (NIBIB)
UNKNOWN
ClinPharm Consulting, LLC
UNKNOWN
Ricerca Biosciences LLC
UNKNOWN
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Cato Research
INDUSTRY
Baxalta now part of Shire
INDUSTRY